Energy Fuels (UUUU)(EFR:CA) – Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

 


Energy Fuels and Team from Penn State University Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

LAKEWOOD, Colo.April 23, 2021 /CNW/ – Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that the U.S. Department of Energy (“DOE“) Office of Fossil Energy and National Energy Technology Laboratory has exercised their option to award Energy Fuels, working with a team from Penn State University, an additional $1.75 million to complete a feasibility study (“Feasibility Study“) on the production of rare earth element (“REE“) products from natural coal-based resources, as well as from other materials such as REE-containing ores like the natural monazite ore (“Monazite“) the Company is currently processing at its White Mesa Mill in Utah.

This award follows the DOE providing Energy Fuels a $150,000 contract in 2020 for the successful completion of a conceptual design for the same initiative, resulting in a total award to Energy Fuels of $1.9 million. The Feasibility Study is intended to support a cost estimate for the production of individually separated rare earth oxides and rare earth metals and alloys from coal-based resources or other resources, including Monazite, within the U.S., with a focus on REEs for the production of commodity and defense-related products.

Energy Fuels is already evaluating the potential to develop commercial REE separation, metals, alloys, and other downstream REE capabilities at the White Mesa Mill, or nearby, with the goal of fully integrating a commercial U.S. REE supply chain in the coming years. The Company’s work on the DOE Feasibility Study is expected to complement these efforts and has the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products in the U.S. in the coming years.

“We are pleased to continue our collaboration with the U.S. Department of Energy, as we work together to restore critical U.S. rare earth supply chains available for domestic manufacturing,” stated Mark S. Chalmers, President and CEO of Energy Fuels. “As we continue to ramp-up production of an intermediate rare earth product at the White Mesa Mill in Utah, we are moving forward with designing and developing the infrastructure needed to responsibly produce separated rare earth oxides and other products needed by the electric vehicle, renewable energy, defense and other domestic industries. Furthermore, we believe we can design our infrastructure to process feeds produced in the DOE program as well as the Monazite we are currently processing, for the recovery of uranium and REE products. We believe these kinds of collaborative public-private partnerships will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains.”

About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and is in the process of ramping-up to commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR“) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com. 

Cautionary Note Regarding Forward-Looking Statements: This news release contains “forward-looking information” within the meaning of applicable securities laws in the United States and Canada. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to the outcome of the Feasibility Study; any expectation that the White Mesa Mill will be successful in producing REE carbonate on a commercial basis; any expectation that Energy Fuels will be successful in developing U.S. separation, metals or metal/alloy capabilities at the White Mesa Mill or nearby, or otherwise fully integrating a low cost U.S REE supply chain in the future; any expectation with regard to the cost of producing and separating REE carbonate at the White Mesa Mill; any expectation that the Company’s work on the Feasibility Study will complement the Company’s current efforts or have the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products; any expectation that the Company’s collaboration with DOE will restore critical U.S. rare earth supply chains available for domestic manufacturing; any expectation that the Company can design its infrastructure to process feeds produced in the DOE program as well as the Monazite it is currently processing, for the recovery of uranium and REE products; and any expectation that the Company’s collaboration with DOE will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: technical difficulties; processing difficulties and upsets; commodity price levels and fluctuations; competition from other facilities domestically and internationally; available supplies of coal-based or other resources that meet commercial specifications; the availability of long-term purchase and supply agreements; capital requirements; the ability of the White Mesa Mill to produce REE carbonate or other REE products that meet commercial specifications on a commercial scale at acceptable costs; market factors, including future demand for REEs; permitting and licensing matters; and legal and regulatory challenges. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

For further information: Investor Inquiries: Energy Fuels Inc., Curtis Moore, VP – Marketing and Corporate Development, (303) 974-2140, or Toll free: (888) 864-2125, investorinfo@energyfuels.com, www.energyfuels.com

Release – CoreCivic (CXW) – Announces 2021 First Quarter Earnings Release and Conference Call Dates


CoreCivic Announces 2021 First Quarter Earnings Release and Conference Call Dates

 

BRENTWOOD, Tenn., April 23, 2021 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2021 first quarter financial results after the market closes on Wednesday, May 5, 2021.  

A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, May 6, 2021, and will be accessible through the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. The live broadcast can also be accessed by dialing 800-367-2403 in the U.S. and Canada, including the confirmation passcode 7487376. An online replay of the call will be archived on our website promptly following the conference call. In addition, there will be a telephonic replay available beginning at 1:00 p.m. central time (2:00 p.m. eastern time) on May 6, 2021, through 1:00 p.m. central time (2:00 p.m. eastern time) on May 14, 2021. To access the telephonic replay, dial 888-203-1112 in the U.S. and Canada. International callers may dial +1 719-457-0820 and enter passcode 8097453.

About CoreCivic

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. 

Contact:    Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
    Media: Steve Owen – Vice President, Communications – (615) 263-3107

QuickChek – April 23, 2021



Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

Ocugen announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering

Research, News & Market Data on Ocugen

Watch recent presentation from NobleCon17



Ocugen up 35% in Midday Trading

Ocugen shares up 35% on optimism after positive results of interim analysis of its Phase 3 study of COVAXIN, a COVID-19 vaccine candidate

Research, News & Market Data on Ocugen

Watch recent presentation from NobleCon17



Energy Fuels and Team from Penn State University Awarded Additional $1.75 Million by U.S. Department of Energy

Energy Fuels announced that the U.S. Department of Energy has exercised their option to award Energy Fuels, working with a team from Penn State University, an additional $1.75 million to complete a feasibility study on the production of rare earth element products

Research, News & Market Data on Energy Fuels

Watch recent presentation from Energy Fuels



CoreCivic Announces 2021 First Quarter Earnings Release and Conference Call Dates

CoreCivic announced that it will release its 2021 first quarter financial results after the market closes on Wednesday, May 5, 2021

Research, News & Market Data on CoreCivic

Watch recent presentation from NobleCon17



Avivagen Announces Largest Single Customer Purchase Order

Avivagen announced that it has received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta™ Livestock from UNAHCO

Research, News & Market Data on Avivagen

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Travelzoo (TZOO) – Risk Reward Relationship Improves Despite Headwinds

Friday, April 23, 2021

Travelzoo (TZOO)
Risk/Reward Relationship Improves Despite Headwinds

Travelzoo is a US-based company which acts as a publisher of travel and entertainment offers. The company informs a varied number of members in Asia Pacific, Europe, and North America, as well as millions of website users, about the best travel, entertainment and local deals available from various companies. It provides travel, entertainment, and local businesses in a flexible manner to the various customer. The company operates in three geographic segments namely Asia Pacific, Europe, and North America. Travelzoo derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on company’s media properties. Most of the company’s revenue is derived from the North America.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Q1 in line with previously lowered expectations. Total company revenues were $14.3 million versus our $13.7 million estimate. The revenues benefited from moderating advertising trends. Adjusted EBITDA was roughly $600,000 versus our $15,000 estimate, benefiting from slightly better gross margins.

    Q2 outlook appears encouraging.  Management guided Q2 revenues to a range of $16 million to $17 million, with expenses to be roughly $15.5 million. Given the improving revenues, the company is expected to swing toward earnings positive in the quarter …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Energy Fuels (UUUU)(EFR:CA) – Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

 


Energy Fuels and Team from Penn State University Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

LAKEWOOD, Colo.April 23, 2021 /CNW/ – Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that the U.S. Department of Energy (“DOE“) Office of Fossil Energy and National Energy Technology Laboratory has exercised their option to award Energy Fuels, working with a team from Penn State University, an additional $1.75 million to complete a feasibility study (“Feasibility Study“) on the production of rare earth element (“REE“) products from natural coal-based resources, as well as from other materials such as REE-containing ores like the natural monazite ore (“Monazite“) the Company is currently processing at its White Mesa Mill in Utah.

This award follows the DOE providing Energy Fuels a $150,000 contract in 2020 for the successful completion of a conceptual design for the same initiative, resulting in a total award to Energy Fuels of $1.9 million. The Feasibility Study is intended to support a cost estimate for the production of individually separated rare earth oxides and rare earth metals and alloys from coal-based resources or other resources, including Monazite, within the U.S., with a focus on REEs for the production of commodity and defense-related products.

Energy Fuels is already evaluating the potential to develop commercial REE separation, metals, alloys, and other downstream REE capabilities at the White Mesa Mill, or nearby, with the goal of fully integrating a commercial U.S. REE supply chain in the coming years. The Company’s work on the DOE Feasibility Study is expected to complement these efforts and has the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products in the U.S. in the coming years.

“We are pleased to continue our collaboration with the U.S. Department of Energy, as we work together to restore critical U.S. rare earth supply chains available for domestic manufacturing,” stated Mark S. Chalmers, President and CEO of Energy Fuels. “As we continue to ramp-up production of an intermediate rare earth product at the White Mesa Mill in Utah, we are moving forward with designing and developing the infrastructure needed to responsibly produce separated rare earth oxides and other products needed by the electric vehicle, renewable energy, defense and other domestic industries. Furthermore, we believe we can design our infrastructure to process feeds produced in the DOE program as well as the Monazite we are currently processing, for the recovery of uranium and REE products. We believe these kinds of collaborative public-private partnerships will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains.”

About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and is in the process of ramping-up to commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR“) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com. 

Cautionary Note Regarding Forward-Looking Statements: This news release contains “forward-looking information” within the meaning of applicable securities laws in the United States and Canada. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to the outcome of the Feasibility Study; any expectation that the White Mesa Mill will be successful in producing REE carbonate on a commercial basis; any expectation that Energy Fuels will be successful in developing U.S. separation, metals or metal/alloy capabilities at the White Mesa Mill or nearby, or otherwise fully integrating a low cost U.S REE supply chain in the future; any expectation with regard to the cost of producing and separating REE carbonate at the White Mesa Mill; any expectation that the Company’s work on the Feasibility Study will complement the Company’s current efforts or have the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products; any expectation that the Company’s collaboration with DOE will restore critical U.S. rare earth supply chains available for domestic manufacturing; any expectation that the Company can design its infrastructure to process feeds produced in the DOE program as well as the Monazite it is currently processing, for the recovery of uranium and REE products; and any expectation that the Company’s collaboration with DOE will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: technical difficulties; processing difficulties and upsets; commodity price levels and fluctuations; competition from other facilities domestically and internationally; available supplies of coal-based or other resources that meet commercial specifications; the availability of long-term purchase and supply agreements; capital requirements; the ability of the White Mesa Mill to produce REE carbonate or other REE products that meet commercial specifications on a commercial scale at acceptable costs; market factors, including future demand for REEs; permitting and licensing matters; and legal and regulatory challenges. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

For further information: Investor Inquiries: Energy Fuels Inc., Curtis Moore, VP – Marketing and Corporate Development, (303) 974-2140, or Toll free: (888) 864-2125, investorinfo@energyfuels.com, www.energyfuels.com

CoreCivic (CXW) – Announces 2021 First Quarter Earnings Release and Conference Call Dates


CoreCivic Announces 2021 First Quarter Earnings Release and Conference Call Dates

 

BRENTWOOD, Tenn., April 23, 2021 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2021 first quarter financial results after the market closes on Wednesday, May 5, 2021.  

A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, May 6, 2021, and will be accessible through the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. The live broadcast can also be accessed by dialing 800-367-2403 in the U.S. and Canada, including the confirmation passcode 7487376. An online replay of the call will be archived on our website promptly following the conference call. In addition, there will be a telephonic replay available beginning at 1:00 p.m. central time (2:00 p.m. eastern time) on May 6, 2021, through 1:00 p.m. central time (2:00 p.m. eastern time) on May 14, 2021. To access the telephonic replay, dial 888-203-1112 in the U.S. and Canada. International callers may dial +1 719-457-0820 and enter passcode 8097453.

About CoreCivic

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. 

Contact:    Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
    Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Avivagen (VIVXF)(VIV:CA) – Announces Largest Single Customer Purchase Order


Avivagen Announces Largest Single Customer Purchase Order

 

 4 tonne order is the largest single shipment purchase in Avivagen’s history
 Purchase order represents more than 40% of previous fiscal year’s total volume

Ottawa, ON / Business Wire/ April 23, 2021 / – Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce it has received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta™ Livestock from UNAHCO. The purchase order is the largest single shipment purchase order of OxC-beta™ to date and represents a 10% increase in size over its previous record single shipment order.

“UNAHCO has been amongst the earliest adopters of OxC-beta™ for use in swine, and recently poultry, and its continued growth in order frequency and size is a clear indicator of the value that our product brings to the livestock feed production market,” said Kym Anthony, Chief Executive Officer, Avivagen Inc.  “We continue to add new applications and markets for OxC-beta™ worldwide that, taken together with our ongoing relationships with great and growing customers like UNAHCO, are providing dramatic growth potential and success for Avivagen. We also want to thank our colleagues who worked with the government in the Philippines to get this order cleared during challenging COVID-19 restrictions.”

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to the future delivery of product based on the purchase order received, Avivagen’s expectations as to growth of its branding in certain jurisdictions, continued distribution and acceptance of Avivagen’s technology, anticipated growth in demand for Avivagen’s products,  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagens products,  the customer plans may change due to many reasons Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds,  and fulfillment of the order may be delayed beyond current expectation, or in the worst case cancelled, in each case due to many factors, many of which are outside of Avivagens control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Indonesia Energy Corp (INDO) – INDO Begins Drilling

Friday, April 23, 2021

Indonesia Energy Corp (INDO)
INDO Begins Drilling

Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. It holds two oil and gas assets through its subsidiaries in Indonesia: one producing block (the Kruh Block) and one exploration block (the Citarum Block). The Kruh Block is located to the northwest of Pendopo, Pali, South Sumatra. The Citarum Block is located to the south of Jakarta.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    INDO begins drilling in the Kruh Block. Well Kruh-25 is the first of three back-to-back wells. Management expects to drill 5 wells in 2021, 6 in 2022, and 7 in 2023. Other details regarding drilling depth, time to drill, and expected initial production were unchanged. The announcement has been long awaited, with the estimated start date being pushed back several times.

    Drilling had been delayed by COVID and regulatory approval.  INDO initially planned to drill 6 Kruh wells in 2020 with the first well beginning shortly after renewing an operating agreement in May 2020. In July 2020, management pushed back first well expectations to September 2020. In September, it pushed back expectations to “one well in 2020”. In December, management cited a January 2021 start …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Avivagen (VIVXF)(VIV:CA) – Announces Largest Single Customer Purchase Order


Avivagen Announces Largest Single Customer Purchase Order

 

 4 tonne order is the largest single shipment purchase in Avivagen’s history
 Purchase order represents more than 40% of previous fiscal year’s total volume

Ottawa, ON / Business Wire/ April 23, 2021 / – Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce it has received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta™ Livestock from UNAHCO. The purchase order is the largest single shipment purchase order of OxC-beta™ to date and represents a 10% increase in size over its previous record single shipment order.

“UNAHCO has been amongst the earliest adopters of OxC-beta™ for use in swine, and recently poultry, and its continued growth in order frequency and size is a clear indicator of the value that our product brings to the livestock feed production market,” said Kym Anthony, Chief Executive Officer, Avivagen Inc.  “We continue to add new applications and markets for OxC-beta™ worldwide that, taken together with our ongoing relationships with great and growing customers like UNAHCO, are providing dramatic growth potential and success for Avivagen. We also want to thank our colleagues who worked with the government in the Philippines to get this order cleared during challenging COVID-19 restrictions.”

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to the future delivery of product based on the purchase order received, Avivagen’s expectations as to growth of its branding in certain jurisdictions, continued distribution and acceptance of Avivagen’s technology, anticipated growth in demand for Avivagen’s products,  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagens products,  the customer plans may change due to many reasons Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds,  and fulfillment of the order may be delayed beyond current expectation, or in the worst case cancelled, in each case due to many factors, many of which are outside of Avivagens control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Analysis of a SPAC

 


Analysis of a Special Purpose Acquisition Company
(Part of a Channelchek Series on SPACs)

 

Special purpose acquisition companies (SPACs) are an increasingly popular vehicle for various transactions, including transitioning a business from a private company to a publicly traded corporation.  Some market participants believe that, through a SPAC transaction, a private company can become a publicly-traded company with a higher level of certainty as to pricing and control over deal terms when compared to a traditional initial public offerings (IPOs).

Analysis of a SPAC is part of a series of ongoing educational pieces published by Channelchek on the subject. From this edition, you should expect to gain a better understanding of:

  • Investor rights when a SPAC is in its shell company stage
  • Financial interests and motivations of SPAC sponsors
  • Evaluating investor options as it begins to de-SPAC
  • Warrants and possible impact on stockholders

Common Acquisition/Merger

Typically, a SPAC acquires or merges with a private company after a period of fewer than two years after the SPACs own introduction to the market as an IPO. Unlike a fully functioning business going public, a SPAC is non-operating and yet to be further defined aside from objective. Its primary asset is the cash which was proceeds from the IPO and perhaps contributions of founding members and sponsors.

Investing in a SPAC offering should involve a review of the potential success of the management team that formed the SPAC and the expectation that they will be able to acquire or combine with an operating business.  That acquisition or combination is known as the initial business combination; it is when the SPAC de-SPACs and is trading as other functioning public corporations do.  One consideration that must be understood is a SPAC may identify in its IPO prospectus a specific industry or business that it will target. However, it is not obligated to pursue a target in that suggested industry.

The Initial Business Combination

As the SPAC identifies the opportunity of an initial business combination, its founders and sponsors negotiate with the target before presenting for approval to SPAC shareholders. If approved by a majority vote, they execute on the takeover.  The transaction is commonly structured as a reverse merger where the operating company merges with and into the publicly traded SPAC.  The initial business may be structured in various ways; however, the combined company, once the transaction is executed, is a publicly-traded company and carries on the business it had been engaged in, while the SPAC designation ceases to exist (de-SPAC).

Evaluating an Investment in a SPAC  

Before the initial business combination, retain a copy of the prospectus and other reports (periodic and current field).  If there is third-party research available (quality research by credentialed providers), read and develop an understanding of the analyst’s evaluation. It’s important to comprehend the terms of any investment and the expectations of management.  While SPACs are generally uniform in structure and may be subject to certain minimum exchange listing requirements, it’s important to understand the specific features of any SPAC that you may commit money to. Part of this understanding includes the equity interests held by the sponsor and how they were derived (purchased versus nominal consideration).  Since the SPAC doesn’t have an operating history to evaluate, it’s important to evaluate the background of SPAC management, you should read and understand a SPAC’s IPO prospectus and periodic and current reports in the SEC’s EDGAR database.
 

SPACs generally invest the proceeds from the IPO in relatively safe, interest-bearing instruments. You’ll find the acceptable deposits or investments listed in the IPO prospectus, there are no regulatory guidelines for cash investments, so this section is important to visit.  Also, understand what anyb investment earnings are to be used for. SPACs often use the interest on the trust or escrow account assets to pay taxes.

 

 

Investor Redemption Option

A SPAC provides its investors with the option to redeem their shares rather than become a shareholder of the combined company.  Should the SPAC not be able to move forward and complete a business combination, shareholders are beneficiaries of the trust and are entitled to their pro-rata share of the amount left on deposit in the trust account. This is another area to focus on when reviewing the SPAC prospectus before committing to an investment. Review the IPO prospectus to understand the terms of the trust account, including your redemption rights and the circumstances in which cash may be released from the account.

If you purchased your shares on the open market at a cost different from the SPAC price (usually $10), your shares are redeemed at the same valuation as those that invested at the IPO price. If you own shares at a discount to the IPO price, you may profit (and have a tax situation). If you paid a premium, you will have your shares redeemed at a loss.

Consummation Period

Most
SPACs provide a two-year period for the management to identify and complete an initial business combination transaction.  The time frame is spelled out in the prospectus and should be verified. Some SPACs have opted for shorter periods.  The SPAC’s governing instruments may permit it to extend that time period – understand what you’re investing in.  In some governing documents, if a SPAC wants to extend the search period, it may be required to get shareholder approval.  There is a regulatory maximum if a SPAC lists its securities on an exchange; then it is required to complete an initial business combination within three years of its IPO. 

The current use of SPACs to acquire companies has the effect of increasing competition among SPACs and reducing the potential ideal targets. This should be weighed into your decision when tying up investment capital.

Secondary Trading

Be certain of the class of security that you’re putting in your portfolio. The initial public offering of a SPAC is often structured with securities that include common shares and warrants.  The warrants are contractual arrangements that provide registered holders the right to purchase from the company a specified number of additional shares of common stock in the future at a certain price, often a premium (out of the money) to the stock price when issued.

The initial SPAC unit will trade for some time after the IPO.  Over time, the SPAC common stock and warrants may begin trading on exchanges separately under unique trading symbols.  The SPAC generally files an 8K (Form 8-K ) and issues a press release to make interested parties aware when separate trading is to begin.  Investors who purchase SPAC securities after the IPO on the open market should be aware of whether they are purchasing units, common stock, or warrants.

The terms and stipulations of warrants are unique arrangements individual to each SPAC. It’s important to understand the contractual agreements as either an investor in common stock or in secondary warrants. The Terms will include how many shares warrant holders have the right to purchase (possible dilution of common shareholders) and as an investor how many shares a warrant would allow, the price at and period during which shares may be purchased, any circumstances under which the SPAC may be permitted to redeem the warrants, and the warrant expiration date. These terms and quantity can be found in the IPO prospectus for the SPAC.

 

 

Initial Business Combination Action Items

As the SPAC is successful in identifying a target for an initial business combination, shareholders of the SPAC can expect to receive a proxy statement to solicit shareholder approval. Shareholders will have the opportunity to vote on the transaction and as is standard in most SPAC documents, either remain a shareholder after the initial business combination or redeem their shares at its pro-rata amount as outlined earlier. In some cases, SPAC sponsors and affiliates may have enough votes to approve the transaction without a full shareholder vote.

This is a critical step, the successful (in terms of finding a target and transacting) SPAC now transitions from having assets that are a trust account to owning an operating company.  Depending on how you as an investor view the business being transacted on and whether it represents value to you, you have a window to be in or out at a pro-rata amount.

If the SPAC seeks shareholder approval of an initial business combination, it will provide shareholders with a proxy in advance of the shareholder vote.  In cases where the SPAC does not solicit the approval of public shareholders, because certain shareholders, such as the sponsor and its affiliates, hold enough votes to approve the transaction, it will provide shareholders with an Information Statement in advance of the completion of the initial business combination. 

The Proxy or Information Statement will contain information about the business of the company to be acquired, their financial statements, parties to the transaction, and the terms of the initial business combination transaction, including the capital structure of the combined entity. 

What Else?

In addition, the SPAC may require additional financings to fund the initial business combination, and those financings often involve the sponsors.  As a result, the interests of the sponsors may further diverge from your interests.  For example, additional funding from the sponsors may dilute your interest in the combined company or may be provided in the form of a loan or security that has different rights from your investments.

To learn more about a sponsor’s interests in a SPAC, review the Principal Stockholders and Certain
Relationships
and Related Party Transactions sections of a SPAC’s IPO prospectus.  You can learn more about an initial business combination and the sponsor’s interest from the Proxy Statement, Information Statement, or Tender Offer Statement.

 

You May Also Be Interested In:

The Lifecycle of a SPAC

Special Purpose Acquisition Corporations (SPAC) Attracting Investors



How PPI Impacts CPI Numbers

IRA Investments and Small-Cap Stocks


Stay up to date. Follow us:

           


Stay up to date. Follow us:

Ocugen (OCGN) – Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market


Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

 

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering. The offering is expected to close on or about April 27, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be approximately $100 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses.

The shares of common stock described above are being offered pursuant to an automatic “shelf” registration statement (File No. 333-254550) filed with the Securities and Exchange Commission (“SEC”) on March 22, 2021 which automatically became effective pursuant to SEC rules. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (646) 975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
IR@Ocugen.com

Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042

Release – Ocugen (OCGN) – Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market


Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

 

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering. The offering is expected to close on or about April 27, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be approximately $100 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses.

The shares of common stock described above are being offered pursuant to an automatic “shelf” registration statement (File No. 333-254550) filed with the Securities and Exchange Commission (“SEC”) on March 22, 2021 which automatically became effective pursuant to SEC rules. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (646) 975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
IR@Ocugen.com

Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042

CO2 Emissions by Country


CO2 Emissions by Country

 

Each Country’s Share of Emissions (GT=Gigaton)

 

Countries across the globe have varying populations and are at different stages of development which influences their CO2 output along with emitting other greenhouse gases into the atmosphere. The International Energy Agency has compiled related data in the pie chart above and tables below. The amount per country and amount per capita are startling in their differences.

 

The 21 Countries that Emitted the Most Carbon Dioxide  

 

 

Measured in gigatons, the top CO2-producing countries are among the most populous and industrial (above). Looking at how much CO2 is released per capita and the list provides a very different perspective. India moves down from #3 to #21, and Kazakstan which was #21 moves up to #2.

 

 

The story that emerges from this data is that, in general, developed countries and major emerging economy nations contribute the most in total carbon dioxide emissions while some developing nations lead in the average emitted carbon dioxide per resident.

 

Sources:

http://energyatlas.iea.org/#!/tellmap/1378539487

https://www.ucsusa.org/resources/each-countrys-share-co2-emissions

 

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us: